![Kaplan-Meier curves for overall survival. OS overall survival, non-MDT... | Download Scientific Diagram Kaplan-Meier curves for overall survival. OS overall survival, non-MDT... | Download Scientific Diagram](https://www.researchgate.net/publication/342628025/figure/fig2/AS:908830661697536@1593693523052/Kaplan-Meier-curves-for-overall-survival-OS-overall-survival-non-MDT-non.png)
Kaplan-Meier curves for overall survival. OS overall survival, non-MDT... | Download Scientific Diagram
![A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine](https://www.thelancet.com/cms/attachment/4c56dec5-310c-4e24-ab78-fbf95f7c8023/gr1.jpg)
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine
![Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy](https://abstracts.mirrorsmed.org/sites/default/files/908-0.jpg)
Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy
Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection | PLOS ONE
![Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative | BMC Pulmonary Medicine | Full Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative | BMC Pulmonary Medicine | Full](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12890-020-01270-z/MediaObjects/12890_2020_1270_Fig4_HTML.png)
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative | BMC Pulmonary Medicine | Full
![Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/4/e002114/F2.large.jpg)
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
![Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/3/3/e001802/F1.large.jpg?width=800&height=600&carousel=1)
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
![Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-018-0061-6/MediaObjects/41416_2018_61_Fig1_HTML.jpg)
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer
![PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/eb56a0ed555af54134d5949c8b856bff15592fe4/3-Figure1-1.png)
PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar
![The overall survival (OS) and progression-free survival (PFS) of patients with tumors involving the subventricular zone (SVZ). The overall survival (OS) and progression-free survival (PFS) of patients with tumors involving the subventricular zone (SVZ).](https://s3-eu-west-1.amazonaws.com/ppreviews-plos-725668748/5038006/preview.jpg)
The overall survival (OS) and progression-free survival (PFS) of patients with tumors involving the subventricular zone (SVZ).
![Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-020-0805-y/MediaObjects/41416_2020_805_Fig1_HTML.png)
Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer
![Proposal of a Useful Surrogate Endpoint of the Overall Survival in Patients Undergoing Pulmonary Metastasectomy: The Time to Local Therapy Failure | SpringerLink Proposal of a Useful Surrogate Endpoint of the Overall Survival in Patients Undergoing Pulmonary Metastasectomy: The Time to Local Therapy Failure | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00268-019-05071-2/MediaObjects/268_2019_5071_Fig3_HTML.png)
Proposal of a Useful Surrogate Endpoint of the Overall Survival in Patients Undergoing Pulmonary Metastasectomy: The Time to Local Therapy Failure | SpringerLink
![Surrogate endpoints for overall survival in advanced non‑small‑cell lung cancer patients with mutations of the epidermal growth factor receptor gene Surrogate endpoints for overall survival in advanced non‑small‑cell lung cancer patients with mutations of the epidermal growth factor receptor gene](https://www.spandidos-publications.com/article_images/mco/2/5/MCO-02-05-0731-g02.jpg)
Surrogate endpoints for overall survival in advanced non‑small‑cell lung cancer patients with mutations of the epidermal growth factor receptor gene
![Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma - ScienceDirect Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2468294220301076-gr1.jpg)
Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma - ScienceDirect
![Difference in median overall survival (OS) (months) of individual therapies per International Classification of Diseases 10th revision (ICD–10) category. - ppt download Difference in median overall survival (OS) (months) of individual therapies per International Classification of Diseases 10th revision (ICD–10) category. - ppt download](https://slideplayer.com/98/17007632/big_thumb.jpg)
Difference in median overall survival (OS) (months) of individual therapies per International Classification of Diseases 10th revision (ICD–10) category. - ppt download
![Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 24 Issue 9 (2017) Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 24 Issue 9 (2017)](https://erc.bioscientifica.com/view/journals/erc/24/9/images/large/full-475fig2.jpeg)
Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 24 Issue 9 (2017)
![PDF] Progression Free Survival (PFS) and Overall Survival (OS) in Patients Receiving 3 Targeted Therapies (TTS) for Metastatic Renal-Cell Carcinoma (MRCC) by Roberto Iacovelli, Matteo Santoni, G. Di Lorenzo, L. Cerbone, Massimo PDF] Progression Free Survival (PFS) and Overall Survival (OS) in Patients Receiving 3 Targeted Therapies (TTS) for Metastatic Renal-Cell Carcinoma (MRCC) by Roberto Iacovelli, Matteo Santoni, G. Di Lorenzo, L. Cerbone, Massimo](https://og.oa.mg/Progression%20Free%20Survival%20(PFS)%20and%20Overall%20Survival%20(OS)%20in%20Patients%20Receiving%203%20Targeted%20Therapies%20(TTS)%20for%20Metastatic%20Renal-Cell%20Carcinoma%20(MRCC).png?author=%20Roberto%20Iacovelli,%20Matteo%20Santoni,%20G.%20Di%20Lorenzo,%20L.%20Cerbone,%20Massimo%20Aglietta,%20Cristina%20Masini,%20Maria%20Olga%20Giganti,%20Caterina%20Messina,%20Cora%20N.%20Sternberg,%20G.%20Procopio)
PDF] Progression Free Survival (PFS) and Overall Survival (OS) in Patients Receiving 3 Targeted Therapies (TTS) for Metastatic Renal-Cell Carcinoma (MRCC) by Roberto Iacovelli, Matteo Santoni, G. Di Lorenzo, L. Cerbone, Massimo
![Overall survival (OS) by circulating tumor DNA (ctDNA) status in patients with post-operative muscle-invasive urothelial carcinoma (MIUC) treated with atezolizumab (atezo): update from IMvigor010 - UROONCO Bladder Cancer Overall survival (OS) by circulating tumor DNA (ctDNA) status in patients with post-operative muscle-invasive urothelial carcinoma (MIUC) treated with atezolizumab (atezo): update from IMvigor010 - UROONCO Bladder Cancer](https://eau-bb-01.s3.amazonaws.com/webcasts/EAU22/1313581ca4fd152b6f8cec0b88292a11ae664b/131358/media/Slide1.jpg)